SLC39A10通过MAPK14 (p38α) 途径驱动M2巨细胞极化和胃癌的进展
Yinhua Liang1, Mengting Li1, Chihao Zhang1
1Department of General Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
iScience
|January 15, 2026
概括
载体SLC39A10通过激活瘤细胞中的MAPK14并促进M2巨细胞的两极分化,驱动胃癌 (GC) 的进展. 这个轴为免疫抑制瘤微环境 (TME) 提供燃料,提供治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 胃癌 (GC) 的进展与免疫抑制性瘤微环境 (TME) 有关.
- 载体SLC39A10与GC恶性进展有关,影响瘤细胞和巨细胞.
- 在TME中SLC39A10的细胞类型特异性作用和调控机制尚未完全理解.
研究的目的:
- 为了研究SLC39A10在胃癌中的细胞类型特异性功能.
- 阐明SLC39A10影响瘤微环境的调节机制.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 用于分析细胞类型特定的基因表达.
- 为了验证发现,进行了功能性实验.
- 分析的重点是瘤细胞和瘤相关巨细胞 (TAMs) 之间的相互作用.
主要成果:
- 在瘤细胞中SLC39A10 (oeSLC39A10) 的过度表达激活了MAPK14信号通路.
- 与瘤相关的巨细胞 (TAMs) 呈现出极化M2状态.
- 通过IL-10和TGF-β之间的瘤细胞和M2 TAMs之间的细胞间通信促进了瘤增殖和血管生成.
结论:
- 在胃癌中发现了一种新的SLC39A10-MAPK14-M2巨细胞调节轴.
- 这个轴极大地重塑了免疫微环境,推动了GC的进展.
- 准这个轴是一个潜在的治疗策略,可以修改TME并抑制GC的进展.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
MAPK Signaling Cascades
7.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.9K


